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Abstract 
Development of a TB vaccine for cattle is a research priority in Great Britain. Two challenges need to be addressed. 
Firstly, vaccine strategies enhancing the efficacy of M. bovis bacille Calmette Guérin (BCG), currently the only 
potentially available TB vaccine, and secondly the development of a diagnostic test to be used alongside vaccination to 
differentiate vaccinated and infected animals (DIVA test). Significant progress in developing TB vaccines for cattle has 
been made over the last 7 years. Specifically: (i) DNA, protein, or viral subunit  subunit vaccines used in combination 
with BCG have been shown to give superior protection against experimental challenge in cattle than BCG (heterologous 
prime-boost), (ii) neonatal BCG vaccination provides protection, (iii)  prototype reagents that allow discrimination 
between vaccinated and infected animals have been developed; and (iv) and correlates of disease severity have been 
identified that can predict the success or failure of vaccination. The present overview provides details of some of these 
advances.  [Ethiop.J.Health Dev. 2008;22(Special Issue):100-104] 
 
Introduction 
In 1996, an independent scientific committee reviewed the 
problem of bovine TB in GB. One of the recommendations 
put forward was that vaccination of cattle offered the best 
long-term solution for controlling TB in the National 
Herd. Cattle TB vaccination could also be an attractive and 
cost-effective control strategy in developing countries 
where other control strategies are difficult and expensive 
to implement.  The development of novel vaccines against 
bovine TB has to some degree closely followed that of the 
human TB vaccine effort and there is significant alignment 
between the human and bovine TB vaccine programmes 
(1) and vaccines like recombinant viruses aimed at the 
development of human TB vaccines have been already 
tested in cattle (see below).  
 
Mycobacterium bovis Bacille Calmette Guerin (BCG) 
BCG is the most widely used human vaccine in the world. 
It was derived from a strain of M. bovis, which was 
isolated from a cow with tuberculous mastitis. Challenge 
experiments and field trials in cattle since 1919 have 
resulted in data showing a high degree of variability in the 
ability of BCG to protect cattle against infection with 
Mycobacterium bovis, the causative agent of bovine TB, 
almost some degree of protection was imparted in most of 
these studies (see (1-4) for reviews) . Importantly, BCG 
vaccination sensitises animals to the tuberculin skin test, 
and vaccinated animals will therefore, at least for a 
significant period post-vaccination, test positive in the 
classical skin test. For this reason, test and slaughter-based 
control strategies based on tuberculin skin testing were 
favoured above BCG vaccination. More recent 
experimental studies with BCG have confirmed its 
potential to protect cattle to some degree against bovine 
TB by reducing disease severity and pathology (5,9) . In 
addition, BCG vaccination was more effective when 
delivered to neonatal calves than to older animals (10,11). 
BCG has some of the qualities required for a veterinary 
vaccine (low costs, excellent safety profile), but it does not 
confer complete protection and therefore the aim of TB 
vaccine programmes is to improve its efficacy. However, 
the most promising vaccination strategies identified to 
date have mostly involved improving upon BCG 
vaccination rather than replacing it (see below). BCG 
remains the prototype, gold standard vaccine with which 
to judge the efficacy of any novel vaccine. 
 
Cattle models to test TB vaccines 
The fact that cattle TB vaccines can be experimentally 
tested for efficacy directly in the target species is a big 
advantage over human vaccine development. However, to 
be able to compare vaccines tested in different laboratories 
it is important to use standardised infection models. The 
most commonly used experimental infection model infects 
calves via the intratracheal route (Table 1) (7,8). This is a 
robust model resulting in pathology mainly in the lower 
respiratory tract thereby closely reflecting the pathology 
seen in the majority of infected cattle. Its advantages are 
that almost 100% of infected animals produce productive 
disease with reproducible location and severity thus 
requiring relatively small group to detect significant 
protection. Its short duration (3-4 months post-infection) 
also make it attractive. Potential disadvantages are that, 
due to the relatively high infection doses required to 
achieve infection and disease in most animals, the immune 
system can be overwhelmed and potentially effective 
vaccines could be classified as non-effective. To 
overcome some of these limitations, we have developed a 
vaccination model where transmission of disease is 
facilitated by in-contact with naturally infected cattle 
(Table 1). The advantages are that a natural route and 
infective dose is used, which is unlikely to overwhelm the 
immune system, and that data generated in this model will 
be highly relevant to the actual field situation to guide the 
design of field trials. The disadvantages are larger group 
sizes necessary to achieve the required statistical power, 
due to the lower infection rates compared to intratracheal 
infection. Encouragingly, our preliminary experiments 
conducted in GB have demonstrated a relatively high 
transmission rate (>50% based on immunological 
conversion of in-contact animals to interferon-gamma 
(IFN-
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Vordermeier et al., unpublished data) potentially allowing 
smaller group sizes. As part of the Wellcome Trust project 
‘Bovine tuberculosis in the developing world’ (Animal 
Health in the developing world initiative), a similar in-
contact transmission experiment is at the moment being 
conducted in Ethiopia to test vaccine efficacy after 
neonatal BCG vaccination.  Vaccines giving promising 
results may then be tested in larger field trials, which 
would likely require large numbers of cows that would run 
for a considerable time.  
 
Table 1: Examples of cattle models to test vaccines 
Model Advantages Disadvantages 
Experimental challenge:  
intratracheal model 
‘Few’ animals required (n <10-12/group):  
100 % infection rates of control animals 
Immune system may be overwhelmed  
without giving vaccine a chance (high 
challenge 
 dose: 1-5000 CFU) 
 Short duration (3-4 months): highly 
standardised,  
synchronised infection, defined infection 
strain,  
defined disease kinetics and pathology) 
 
‘Field experiment’ 
In contact transmission 
Natural route and infective dose:  data 
highly relevant for trial designs 
More animals required (>20/group): low  
infection rates of controls 
  Long in-contact period (12 months):  
no synchronised infection, disease 
kinetics not defined,  
pathology less defined 
Field trial Real-life situation:  routes, doses, 
management 
Very large numbers required (n = 100-
1000s) 
  Long and expensive (years) 
 
Recent progress in developing cattle TB vaccines that 
are better than BCG vaccines 
Several strategies have been implemented to improve the 
efficacy of BCG, namely the use of subunit vaccines in the 
form of DNA vaccines, protein subunit vaccines 
administered with a suitable adjuvant, live recombinant 
vaccines like attenuated recombinant viruses expressing 
mycobacterial antigens, or recombinant BCG expressing 
additional antigens not, or under-expressed in BCG. 
Another possible strategy involves the development of 
rationally attenuated M.bovis strains (see (12-14) for 
reviews. The practicality of these strategies have been 
greatly facilitated by the elucidation of the genome 
sequences of M. bovis, M. tuberculosis, and M. bovis BCG 
(Pasteur) (15-17). 
 
Recent results in cattle have also shown that the most 
effective vaccination strategies against bovine TB have 
been based on priming the immune system with BCG 
followed by boosting with subunit vaccines (heterologous 
prime-boost strategy) containing protective antigens that 
are present in BCG. Heterologous prime-boost 
immunisation strategies involve using two different 
vaccines, each expressing the same antigen. 
 
Heterologous prime-boost strategies based on DNA 
vaccines. DNA vaccines can be useful as part of 
heterologous prime-boost protocols. We tested 
heterologous prime-boost protocols in cattle based on 
priming the immune response with a cocktail of 3 DNA 
vaccines encoding the mycobacterial proteins, HSP65, 
HSP70 and APA (which were not protective by 
themselves), followed by boosting with BCG 6 (Table 2). 
This induced significant enhancement of protection in six 
parameters used to determine vaccine efficacy, compared 
to BCG which induced significant protection in only 2/6 
of these parameters (6). Subsequent experiments showed 
that superior protection to BCG could be achieved with 
this combination of vaccines irrespective of whether the 
DNA vaccines or BCG were used for the priming 
immunisation (18) (Table 2). 
 
Heterologous prime-boost strategies based on protein 
subunits. Conceptually, protein subunits are very 
attractive. However, in contrast to DNA vaccines, protein 
subunits are unlikely to induce cellular immune responses 
in the absence of an adjuvant. Therefore, a high priority 
for the development of protein subunit vaccines is the 
identification of adjuvants that enhancing the development 
of cellular immune responses in cattle. A recent important 
development has been the definition of CpG motifs as 
adjuvant units within DNA vaccines (see (19) for review). 
Synthetic oligonucleotides containing such CpG motifs 
can be synthesised to produce short immuno-stimulatory 
sequences (CpG ODN), which can be added to vaccine 
formulations to enhance immunogenicity. Therefore, M. 
bovis culture filtrate proteins (CFP) were used in 
conjunction with such CpG ODN as cattle TB vaccines 
and they significantly enhanced the cellular immune 
responses of CFP Importantly, significant protection was 
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Table 2: Vaccine strategies improving BCG efficacy in experimental challenge experiments 
Study N Vaccine Antigen Adjuvant/ live vector Comment Reference 
1 DNA/BCG DNA vaccine cocktail: 
HSP65,HSP70, Apa 
None (‘in-built’ adjuvant 
activity of DNA 
vaccines) 
BCG Pasteur, 6 
months old calves 
6 
2 DNA/BCG or 
BCG/DNA 
As above None (‘in-built’ adjuvant 





3 BCG/protein M. bovis CFP Emulsigen/bovine 
specific CpG ODN 
(ODN2007) 
BCG Pasteur, 6 
months old calves 
21 
4 BCG/MVA85A Ag85A Attenuated vaccinia 
virus (modified vaccinia 
Ankara strain, MVA) 




23, and  
unpublished 
data 
5 BCG/Ad85A Ag85A Attenuated, replication-
deficient human 
adenovirus type 5 









animals vaccinated with CFP plus CpG ODN, although the 
protective efficacy was inferior to that observed after BCG 
vaccination (20). 
 
Based on these findings, further prime-boost experiments 
were performed in cattle using culture filtrate proteins 
delivered in the presence of CpG containing ODN to boost 
primary immune responses induced by BCG. Groups of 
cattle were vaccinated with either BCG, with BCG and 
CFP plus CpG at the same time followed by two CFP/CpG 
boosts. The results indicated that boosting BCG with CFP 
in CpG gave superior protection than vaccination with 
BCG alone.  (Table 2) (21). 
 
Heterologous prime-boost strategies based on 
recombinant viruses. Some to the advantages of live 
attenuated viruses over protein subunit vaccines are better 
induction of strong cellular immunity, and potentially 
lower production costs and simplified batch release test 
protocols. The first Phase I human trial of a new TB 
vaccine was based on a heterologous prime-boost strategy 
involving boosting BCG-mediated immunity with an 
attenuated vaccinia virus expressing Ag85A of M. 
tuberculosis (MVA85A) (22). 
 
So far, in a collaborative study with the group of Professor 
Adrian Hill at Oxford University, we have performed 
immunogenicity studies of the BCG/MVA85A 
heterologous prime-boost regimen in cattle. Prime-boost 
protocols using recombinant MVA85A and BCG in either 
combination resulted in significantly higher frequencies of 
Ag85-specific IFN-
or BCG used alone. The most promising combination was 
BCG priming followed by one MVA85A boost (23). 
Similarly, we have shown that a prime boost protocol 
applied to cattle that consisted of BCG priming followed 
by heterologous boosting with a recombinant adenovirus 
expressing the same antigen, Ag85A, (Ad85A) developed 
by Professor Xing’s group at McMaster University, 
Toronto, Canda (24) resulted in superior antigen-specific 
IFN-  T cell 
memory compared to BCG vaccination alone (24). 
Furthermore, in a recent challenge experiment using the 
intratracheal infection route, we could demonstrate that 
both MVA85A and Ad85A when used to boost BCG-
induced immunity conferred significant protection, 
superior to BCG vaccination alone (Table 2). 
 
Thus, significant advances have been made to develop 
prototype vaccine strategies that can enhance BCG 
vaccination efficacy based on DNA, protein and viral 
subunit vaccination. Further work is required to determine 
which of these approaches is the most effective, and how 
efficacy determine in experimental challenge experiments 
will translate into field efficacy. Thus, these candidates 
will be tested in the model involving in contact challenge 
as described above. In addition, it will be necessary to 
define, in addition to Ag85A, further protective antigens 
that can then be used as subunit vaccine candidates. This 
work is on-going, but further discussion is beyond the 
scope of this review.  
 
Differential diagnosis of infected from vaccinated 
individuals, and correlates of protection.  
In order to use a vaccine as part of a control strategy for 
bovine TB, discrimination between infected and 
uninfected vaccinated animals (so-called DIVA test) is a 
pre-requisite so that test and slaughter control strategies 
can be carried out alongside vaccination regimens. Over 
the last decade, encouraging progress has been made to 
make the implementation of a DIVA strategy alongside 
effective cattle TB vaccination likely. Conceptually, 
antigens whose genes are expressed in M. bovis yet absent 
from BCG constitute candidates for DIVA reagents. The 
antigens CFP-10 and ESAT-6 have been shown to be 
useful as diagnostic reagents to discriminate between BCG 
vaccinated and M. bovis-infected cattle (5,25-28) and 
constitute a prototype DIVA reagent. Both proteins are 
encoded by genes located on the RD1 region of the M. 
bovis genome that is deleted from the genomes of all 
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strains of BCG (29-31). The genomes of M. tuberculosis, 
M. bovis and BCG Pasteur have now been sequenced (15-
17) and systematic comparative genome comparison have 
been performed to identify further cattle DIVA antigens 
(25,32-33). 
 
TB vaccine development would be greatly facilitated by 
the definition of immunological correlates/surrogates of 
protection. Although some progress has been made, for 
example by defining ESAT-6 and CFP-10-induced IFN-
responses as inverse correlate of protection (5), further 
surrogates still await closer definition. It is beyond the 
scope of this manuscript to present these advances in detail 
and I refer to recent reviews for more detailed discussion 
(13, 14, 34, 35). 
 
Conclusion 
Significant progress has been made in the development of 
TB vaccines for cattle: Subunit vaccines based on DNA, 
proteins or viral subunits used in combination with BCG 
have resulted in better protection against experimental 
challenge with M. bovis than BCG vaccination on its own. 
BCG vaccination of neonates has also proved to be highly 
protective. DIVA reagents that allow discrimination 
between vaccinated and infected animals have been 
developed.  Finally, correlates of disease severity are 
being actively sought that can predict the success or failure 
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